GLRX3 and cardiac hypertrophy: Therefore, the absence of Grx3 in cardiomyocytes might activate the MLP–calcineurin–NFAT pathway that leads to cardiac hypertrophy and heart failure as seen in our Grx3 CKO mouse model.